Furthermore, Though critical adverse events costs were similar amongst groups, patients receiving ibrutinib experienced the next incidence of some distinct adverse situations including bleeding, hypertension and atrial fibrillation.The proposed technique calculates the nearest beacon b y statistical strategy. The positioning is calculated by RSSI t